Santos Paul D, Davis Amanda, Jandourek Alena, Smith Alexander, David Friedland H
J Chemother. 2013 Dec;25(6):341-6. doi: 10.1179/1973947813Y.0000000144. Epub 2013 Dec 6.
The Clinical Assessment Program and TEFLARO Utilization Registry (CAPTURE) is a multicentre retrospective cohort study in the USA describing treatment of acute bacterial skin and skin structure infection (ABSSSI) with ceftaroline fosamil (CPT-F). Charts for review were chosen by random selection. Among 647 evaluable patients, 52% were obese, 46% had diabetes mellitus (DM), and 19% had peripheral vascular disease (PVD). Methicillin-resistant Staphylococcus aureus (MRSA) was recovered in 28% and methicillin-susceptible S. aureus (MSSA), 11%. Antibiotics were administered prior to CPT-F treatment in 80%, and concurrently in 39%. Clinical success overall was 85%; in patients with DM, 83%; with PVD, 76%; and in obese patients, 88%. Clinical success was ≥ 79% across all infection types; 81% for MRSA and 83% for MSSA; and 86% for ceftaroline monotherapy and 84% for concurrent therapy. These high clinical success rates support CPT-F as an effective treatment option for ABSSSI, including infections due to MRSA and patients with significant co-morbidities.
临床评估项目与替加环素使用登记研究（CAPTURE）是美国一项多中心回顾性队列研究，描述了用头孢洛林酯（CPT-F）治疗急性细菌性皮肤及皮肤结构感染（ABSSSI）的情况。用于回顾的病历通过随机选择确定。在647例可评估患者中，52%为肥胖患者，46%患有糖尿病（DM），19%患有外周血管疾病（PVD）。耐甲氧西林金黄色葡萄球菌（MRSA）检出率为28%，甲氧西林敏感金黄色葡萄球菌（MSSA）检出率为11%。80%的患者在接受CPT-F治疗前使用了抗生素，39%的患者同时使用。总体临床成功率为85%；糖尿病患者中为83%；外周血管疾病患者中为76%；肥胖患者中为88%。所有感染类型的临床成功率均≥79%；MRSA感染患者中为81%，MSSA感染患者中为83%；头孢洛林单药治疗的临床成功率为86%，联合治疗的临床成功率为84%。这些较高的临床成功率支持CPT-F作为ABSSSI的一种有效治疗选择，包括由MRSA引起的感染以及伴有严重合并症的患者。
